The role of tralokinumab in the treatment of atopic dermatitis

This review summarises the promising efficacy and safety results obtained in patients with moderate-to-severe AD treated with tralokinumab, a new biologic agent for the systemic treatment of the disease

Atopic dermatitis (AD) represents the commonest inflammatory skin disorder in the developed world.¹ A staggering one-fifth of the population in those countries is affected by AD.²

The disease frequently begins in childhood with recurrent eczematous lesions, initially in the form of poorly defined, erythematous patches with exudation, blistering and crusting, evolving into scaling, fissuring and skin thickening accompanied by itching and discomfort. The course of the disease can be chronic or show intermittent nature with occasional flares.¹

Currently, despite continuous progress in the understanding of AD, the disease cannot be cured.² Physicians rate the level of disease control as inadequate in many patients with a history of moderate-to-severe AD,³ suggesting the need for more effective therapies to offer patients new options and ultimately fight the disease.

This review summarises the promising efficacy and safety results obtained in patients with moderate-to-severe AD treated with tralokinumab, a new biologic agent for the systemic treatment of the disease.